Dr. Hébert was born in Montréal in 1974. He studied biotechnology, and obtained his Ph.D. in Cellular and Molecular Biology at Laval University in 2003. He then completed a postdoctoral fellowship in human genetics at the Katholieke Universiteit Leuven in Belgium. In 2009, he was recruited as Assistant Professor at Laval University. Dr. Hébert is currently an Associate Professor in the Department of Psychiatry and Neuroscience at Laval University. He is also a researcher (group leader) in the Neuroscience Unit of the Research Center of the CHU de Québec – Laval University.

Dr. Hébert’s work focuses on the biological and molecular mechanisms that cause neuronal death and dementia. Specifically, his research team studies the role of micro-RNAs in the development, diagnosis, and treatment of neurodegenerative diseases such as Alzheimer’s disease, frontotemporal dementia, and Huntington’s disease. Micro-RNAs are small molecules in the body that are similar to DNA and regulate the level of proteins. Dr. Hébert’s pioneering research has shown that many micro-RNAs are deregulated in patients with Alzheimer’s disease, and other types of dementia. Curiously, a number of these molecules can reproduce the pathological and clinical symptoms of dementia in biological models on their own, such as cultured neurons and mice. Dr. Hébert also uses the postmortem human brain as an indispensable tool for his research.

Recently, his work on a potential treatment for Alzheimer’s disease was presented by Le Soleil, the FM93 radio station, and The Alzheimer’s Society of Canada’s Website.

Dr. Hébert has received various awards, including the Alzheimer’s Society of Saskatchewan’s Young Investigator Grant (2010) and the FRQS Junior Research Scholar Career Award (2011, 2014). He has been a spokesperson for the Alzheimer’s Society of Canada (2011). In addition to his commitment to teaching, he regularly participates in various evaluation committees and conferences. Finally, he helps organize events and promote basic Canadian research on Alzheimer’s disease, and related dementias.

CHUL
2705, boulevard Laurier
P-09800
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 49233
+1 418-654-2753
Sebastien.Hebert@crchudeq...

Latest news

75 entries « ‹ 3 of 8 › »

Olde Loohuis NF, Nadif Kasri N, Glennon JC, van Bokhoven H, Hebert SS, Kaplan BB, Martens GJ, Aschrafi A

The schizophrenia risk gene MIR137 acts as a hippocampal gene network node orchestrating the expression of genes relevant to nervous system development and function

Journal Article

Prog Neuropsychopharmacol Biol Psychiatry, 73 , 2017.

Abstract | Links:

Petry FR, Nicholls SB, Hebert SS, Planel E

A Simple Method to Avoid Nonspecific Signal When Using Monoclonal Anti-Tau Antibodies in Western Blotting of Mouse Brain Proteins

Journal Article

Methods Mol Biol, 1523 , 2017.

Abstract | Links:

Hernandez-Rapp J, Rainone S, Goupil C, Dorval V, Smith PY, Saint-Pierre M, Vallée M, Planel E, Droit A, Calon F, Cicchetti F, Hébert SS

microRNA-132/212 deficiency enhances Aβ production and senile plaque deposition in Alzheimer's disease triple transgenic mice

Journal Article

Sci Rep, 6 , 2016.

Abstract | Links:

El Khoury NB, Gratuze M, Petry F, Papon MA, Julien C, Marcouiller F, Morin F, Nicholls SB, Calon F, Hebert SS, Marette A, Planel E

Hypothermia mediates age-dependent increase of tau phosphorylation in db/db mice

Journal Article

Neurobiol Dis, 88 , 2016.

Abstract | Links:

Nicolas G, Wallon D, Goupil C, Richard AC, Pottier C, Dorval V, Sarov-Riviere M, Riant F, Herve D, Amouyel P, Guerchet M, Ndamba-Bandzouzi B, Mbelesso P, Dartigues JF, Lambert JC, Preux PM, Frebourg T, Campion D, Hannequin D, Tournier-Lasserve E, Hebert SS, Rovelet-Lecrux A

Mutation in the 3'untranslated region of APP as a genetic determinant of cerebral amyloid angiopathy

Journal Article

Eur J Hum Genet, 24 (1), 2016.

Abstract | Links:

Gratuze M, Julien J, Morin F, Calon F, Hebert SS, Marette A, Planel E

High-fat, high-sugar, and high-cholesterol consumption does not impact tau pathogenesis in a mouse model of Alzheimer's disease-like tau pathology

Journal Article

Neurobiol Aging, 47 , 2016.

Abstract | Links:

Parsi S, Smith PY, Goupil C, Dorval V, Hebert SS

Preclinical Evaluation of miR-15/107 Family Members as Multifactorial Drug Targets for Alzheimer's Disease

Journal Article

Mol Ther Nucleic Acids, 4 , 2015.

Abstract | Links:

Boutchueng-Djidjou M, Collard-Simard G, Fortier S, Hebert SS, Kelly I, Landry CR, Faure RL

The last enzyme of the de novo purine synthesis pathway 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) plays a central role in insulin signaling and the Golgi/endosomes protein network

Journal Article

Mol Cell Proteomics, 14 (4), 2015.

Abstract | Links:

Papadopoulou AS, Serneels L, Achsel T, Mandemakers W, Callaerts-Vegh Z, Dooley J, Lau P, Ayoubi T, Radaelli E, Spinazzi M, Neumann M, Hebert SS, Silahtaroglu A, Liston A, D'Hooge R, Glatzel M, De Strooper B

Deficiency of the miR-29a/b-1 cluster leads to ataxic features and cerebellar alterations in mice

Journal Article

Neurobiol Dis, 73 , 2015.

Abstract | Links:

Smith PY, Hernandez-Rapp J, Jolivette F, Lecours C, Bisht K, Goupil C, Dorval V, Parsi S, Morin F, Planel E, Bennett DA, Fernandez-Gomez FJ, Sergeant N, Buee L, Tremblay ME, Calon F, Hebert SS

miR-132/212 deficiency impairs tau metabolism and promotes pathological aggregation in vivo

Journal Article

Hum Mol Genet, 24 (23), 2015.

Abstract | Links:

75 entries « ‹ 3 of 8 › »
Signaler des ajouts ou des modifications

Active projects

  • Importance of non-canonical microRNAs in the mammalian brain, from 2020-04-01 to 2025-03-31
  • Preclinical safety, pharmacokinetics, pharmacodynamics, and efficiency of microRNA oligonucleotides for Alzheimer's disease, from 2020-03-01 to 2025-03-31
  • Preclinical safety, pharmacokinetics, pharmacodynamics, and efficiency of microRNA oligonucleotides for Alzheimer's disease, from 2022-04-01 to 2027-03-31

Recently finished projects

  • Étude in vivo des microARNs dans les maladies neurodégénératives, from 2019-07-01 to 2022-06-30
  • microRNA-132: from underlying mechanism of neurodegeneration to therapeutic application in Huntington’s disease, from 2017-04-01 to 2022-03-31
Data provided by the Université Laval research projects registery